Metraipolis › archive › dc_705d67bcbfa3

High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohort — Europe PMC PMID:42081119

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42081119
DOI: 10.1007/s00277-[numero omesso]-1
License (as archived): solo-consultazione
Archived: 2026-11-02T19:16:36.166Z
SHA-256 of the archived text: f69f4e1fa4839be14c13a2c3026254a7240e3487442f92b2d5f40add8c947243
Stable URL of this page: https://metraipolis.com/documento/dc_705d67bcbfa3

How to cite

High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohort — Europe PMC PMID:42081119 — Europe PMC (en), https://europepmc.org/article/MED/42081119 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_705d67bcbfa3 (Metraipolis archive dc_705d67bcbfa3, sha256 f69f4e1fa4839be14c13a2c3026254a7240e3487442f92b2d5f40add8c947243)

BibTeX

@misc{dc705d67bcbfa3,
  title = {High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohort — Europe PMC PMID:42081119},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42081119},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_705d67bcbfa3; sha256 f69f4e1fa4839be14c13a2c3026254a7240e3487442f92b2d5f40add8c947243},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42081119. Agents can read the archived copy with the MCP tool read_document.